ArticleBMC public health2025
Systematic analysis of global ischemic heart disease and hypertensive heart disease burden, 1990-2021: projections to 2050.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ischemic Heart Disease and the Epidemiologic Transition: Progress without Reduction in Global Burden.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIschemic heart disease (IHD) and hypertensive heart disease (HHD) are among the leading causes of mortality and disease burden worldwide. This study, based on the 2021 Global Burden of Disease (GBD) data, systematically evaluated the global disease burden and risk factors of IHD and HHD from 1990 to 2021, and projected their trends through 2050, aiming to provide the latest evidence for the global prevention and control of cardiovascular diseases.
methodsWe extracted the age-standardized rates (ASR) of prevalence, mortality, and disability-adjusted life years (DALYs), as well as the estimated annual percentage change (EAPC) for IHD and HHD from the GBD 2021 database. Data were stratified by sex, age group, 21 global regions, and quintiles of the sociodemographic index (SDI) to elucidate temporal trends in disease burden and risk factors.
resultsFrom 1990 to 2021, global deaths due to IHD increased from 5.367 million (95% uncertainty intervals [UI]: 5.076–5.562) to 8.992 million(95% UI, 8.264–9.531), and deaths due to HHD rose from 714,000 (95% UI: 578,000–795,000) to 1.332 million (95% UI: 1.121–1.469); however, the age-standardized mortality rate(ASMR) for both conditions declined (IHD EAPC = -1.30%, HHD EAPC = -0.68%). Significant regional disparities were evident, with East Asia experiencing a sharp increase in IHD standardized prevalence, and Sub-Saharan Africa exhibiting high HHD mortality rates. The disease burden displayed marked heterogeneity by age and sex: IHD predominantly affected elderly males, whereas HHD incidence increased exponentially after age 45, with a higher burden observed in older females compared to males. SDI was inversely correlated with DALYs rates for both diseases, although some high-SDI regions still reported elevated HHD burdens. Risk factor analysis identified elevated systolic blood pressure as the primary driver, with high body mass index (BMI) and high sodium diets as common secondary contributors. Projections indicate that by 2050, ASMR for both diseases will continue to decline, but prevalence rates are expected to rise driven by population aging.
conclusionIHD and HHD represent significant and escalating global cardiovascular health burdens. Population aging has driven an increase in the absolute burden upward, while uneven regional progress in prevention has exacerbated the situation. This underscores the necessity of developing targeted strategies in risk management, early screening, and context-specific interventions, especially for vulnerable groups such as those in low to middle SDI regions and elderly women. Addressing modifiable risk factors and improving long-term disease burden forecasting are critical to slowing the growth of prevalence and optimizing healthcare resource allocation. Coordinated public health policies and integrated clinical management are essential to mitigate the global impact of IHD and HHD and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.